Testing lanreotide before pancreas surgery to prevent leaks
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests if a medicine called lanreotide, given before surgery, can prevent a common complication (pancreatic leak) after removing part of the pancreas. It is for people with pancreatic cancer or a growth that could become cancer who are scheduled for a specific type of pancreas surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are scheduled to have surgery to remove the tail of the pancreas (distal pancreatectomy) within 60 days.
- You have not had radiation or a special treatment called PRRT for your pancreas in the past.
- You have not used a medicine like lanreotide (called a somatostatin analog) in the last 6 months.
- You do not have a condition that makes it hard for your body to absorb nutrients (malabsorption).
- You do not have severe liver problems and your kidney function is adequate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if octreotide microspheres (a slow-release drug) can prevent pancreatic fistula—a common complication after surgery to remove the tail of the pancreas. The goal is to help patients heal with fewer complications.
This trial tests a new treatment, PTM-101, placed during a laparoscopy procedure for people with pancreatic cancer that can be removed with surgery. It aims to see if adding this treatment before standard chemotherapy helps improve outcomes.
This trial tests if a short course of radiation before surgery can lower the risk of a pancreatic leak (a common complication). It is for people who are overweight, older than 45, and have a small pancreatic duct.
This study looks at specific body chemistry pathways in pancreatic cancer tissue to better understand what may help treatment work. If you are having pancreatic surgery, the researchers will take extra small tissue samples during the operation to study tumor and normal tissue.
This trial tests a new type of stapler (AEON) used during surgery to remove the left part of the pancreas. The goal is to see if it helps reduce the risk of a leak from the pancreas after surgery.
This trial is testing a combination of three chemotherapy drugs (NALIRIFOX) given before surgery to shrink borderline resectable pancreatic cancer. The goal is to help make surgery more successful and improve outcomes.
Hear when a new Pancreatic Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.